Editor Profile

editor profile image is not found.

Dr. Andrei Braester, Ph.D.

Director

Present

Galilee Medical Center

Nahariya

Israel

editor profile QR Code is not found.
No content available to display!!!
  • Hematological Malignancies
  • Clinical Hematology
  • Hematologic Diseases
  • Myelodysplastic Syndromes
  • CLL
  • CML
  • Hematopathology
  • Bone Marrow Diseases
  • Flow Cytometry
  • Braester A, Nusem D, Horn Y: Primary meningococcal pericarditis in a pregnant woman. Int J Card 1986,11:355-8.
  • Varkel Y, Nusem D, Braester A, Horn Y : Pyomyosite -maladie tropicale a incidence croissante dans la region mediterraneene. Sem Hosp Paris 1987, 63:1358-9.
  • Varkel Y, Nusem D, Braester A, Shkolnick T: Kaposi's sarcoma presenting as primary lymphadenopathy in an immunocompetent caucasian adult. Sem Hosp Paris 1988,64: 1507-9.
  • Varkel Y, Braester A, Nusem D, Shkolnick T: Methyldopa induced syndrome of innapropriate ADH secretion and bone marrow granulomatosis. Drug Intell and Clin Pharm 1988. 22: 700-1.
  • Nusem D, Braester A, Horn Y: Primary meningococcal pericarditis: a rare expression of a common infection. A review. Harefuah 1988, 104:293-5.
  • Varkel Y , Braester A, Suprun H, Nusem D, Horn Y: Simultaneous occurrence of Systemic Lupus Erythematosus and Coeliac disease-like features. Postgrad Med J. 1989,65:600-2.
  • Braester A, Varkel Y, Horn Y: Malabsorption and Systemic Lupus Erytematosus (letter): Arch Int Med 1989, 149:1901.
  • Varkel Y, Braester A, Mutlak D, Manaster J: Hypercalcemia complicating Essential Thrombocythemia: Eur J Haematol 1990, 44:204.
  • Shai M, Braester A, Cohen Y: Dermatomyositis as presenting symptom of Hodgkin's disease. Ann Haematol 1991, 63:116-8.
  • Cassel A, Braester A, Quitt M, Froom P, Aghai E: Soluble factors from peripheral blood T -cells of patients with Polycythemia Vera stimulate normal BFU-E (original article). Leukemia 1993,7(9):1370-1373.
  • Braester A, Shai M, Reshef R: Skin manifestation as presenting symptom of gastrointestinal disease. Postgrad Med J 1996,72:761-2.
  • Braester A, Cohen Y, Manaster J: Coexistence of littoral cell angioma in spleen with Evans syndrome. Haema 1999, 2(4):203-5.
  • Braester A, Quitt M: Hydroxyurea as a cause of drug fever. Acta Haematologica 2000, 104:50-1.
  • Zaina A, Horn Y, Manaster J, Braester A, Reshef R: Sarcoidosis with cholangitis component in a patient with autoimmune hemolytic anemia. Isr Med Assoc Journal. 2 (9),2000: 712.
  • Vaisban E, Zaina A, Braester A, Manaster J, Horn Y: High dose corticosteroids induced acute tumor lysis syndrome in a patient with Chronic Lymphatic Leukemia. Ann Haematol (80)2001,15: 314-5.
  • Froom P, Elmalah Y, Braester A, Aghai E, Quitt M: Clodronate in Myelofibrosis:A Case Report. Am J Med Sci 2002;323(2):115-116.
  • Zaina A, Braester A, Goldfeld M, Horn Y: Is a ventilation perfusion mismatch in a lung scan always a sign of pulmonary embolism? A propos a case of Takayasu’s arteritis. Acta Radiologica 2002:43(3),334.
  • Braester A, Laver B: Anagrelide-Induced Erectile Dysfunction. The Ann Pharmacother, 2002:36(7),1291.
  • Vaisban E, Braester A, Musinzon O, Kolin M, Horn Y: Spontaneous tumor lysis syndrome in solid tumors: really a rare condition? Am Med J Sci, 2003,325(1):38-40.
  • Braester A: Pseudothrombocytopenia as a pitfall in the treatment of Essential Thrombocythemia. Eur J Haematol, 2003, 70(4):251-252.
  • Braester A, Elmalah Y, Quitt M: Fatal Fludarabine-induced extensive bone marrow necrosis in a patient with chronic lymphocytic leukemia. Leuk Lymphoma, 2003, 44(10),1835-1836.
  • Braester A, Rosenbaum H, Dar H: Cytogenetic evolution in two Ph positive chronic myeloproliferative disorder patients during treatment with Imatinib. Haema, 2004, 7(3):366-369
  • Braester A, Elmalah I, Quitt M: Peripheral blood picture suggestive of myelodysplasia as a paraneoplastic phenomenon preceding Hodgkin's disease. Haema, 2004,7(4):297-301
  • Vaisban E, Melamed-Snapir Y, Braester A, Cohen H, Nassar F. Bone marrow fibrosis and caseating granulomas associated with intravesicular BCG treatment. European Journal of Internal Medicine, 2005,16(4):301-30.
  • Duek A, Shvidel L, Braester A, Berrebi A: Clinical and immunological aspects of B chronic lymphocytic leukemia associated with autoimmune disorders. IMAJ, 2006, 8(12): 828-831.
  • Kuperman A, Baidousi A, Nasser M, Braester A, Nassar F: Microangiopathic anemia of acute brucellosis – is it a true TTP? Medit J Hemat Infect Dis, 2010, 2(3).
  • Ghoti H, Fibach E, Dana M, Abu Shaban M, Jeadi H, Braester A, Matas Z, Rachmilewitz E. Oxidative stress contributes to hemolysis in patients with hereditary spherocytosis and can be ameliorated by fermented papaya preparation (original article). Ann Hematol. 2010, 90(5):509-13.
  • Braester A: New treatments modalities in Chronic Lymphocytic Leukemia. Medicine-Hematology Update, 2011, 7-9.
  • Bairey O, Ruchlemer R, Rahimi-Levene N, Herishanu Y, Braester A, Berrebi a, Polliack A, Klepfish A, Shvidel L: Presenting features and outcome of chronic lymphocytic leukemia patients diagnosed at age 80 years or more. An ICLLSG study (review article). Ann Hematol, 90(10):1123-9, 2011.
  • Braester A. Is the monoclonal antibodies therapy in chronic lymphocytic leukemia the magic bullet? Oncology, 5:15-17, 2011 (in Hebrew).
  • L. Shvidel , A. Braester, O. Bairey, N. Rahimi-Levene, A. Klepfish, Y. Herishanu, M. Shtalrid, A.Polliack, A. Berrebi , on behalf of the Israeli Study Group on CLL. Survival trends among 1325 patients with chronic lymphocytic leukemia seen over the past 40 years in Israel. Am J Hematol, 86(12):985-92, 2011.
  • L. Shvidel, A. Braester, Bairey O, Rahimi-Levene N, Herishanu Y, Tadmor T, Klepfish A, Ruchlemer R, Shtalrid M, Berrebi A, A. Polliack, on behalf of the Israeli Group on CLL. Cell surface expression of CD25 antigen (surface IL-2 receptor alpha-chain) is not a prognostic marker in chronic lymphocytic leukemia: results of a retrospective study of 281 patients. Ann Hematology, 91(10):1597-1602, 2012.
  • A. Braester, L. Akria, C. Suriu, V. Sonkin : Alemtuzumab and Chronic Lymphocytic Leukemia – a story of love and hate (possible Alemtuzumab-induced myelodysplasia). Acta Haematologica, 2013;129:185-186.
  • D. Merkel, K. Filanovsky, A. Gafter-Gvili, L. Vidal, A. Aviv , M. E. Gatt, I. Silbershatz, Y. Herishanu, A. Arad, T. Tadmor, N. Dally, A. Nemets , O. Rouvio, A. Ronson, K. Herzog-Tzarfati, L. Akria, A. Braester, I. Hellmann, S. Yeganeh, A. Nagler, R. Leiba, M. Mittelman ,Y. Ofran. Predicting infections in high-risk MDS/AML patients, treated with azacitidine: a retrospective multi-center study. Am J Hematol. 2013;88(2):130-4.
  • L. Akria, C. Suriu , A. Braester , HI.Cohen, V. Sonkin, : Rare coexistence of Rosai-Dorfman disease and nodal marginal zone lymphoma complicated by severe life threatening autoimmune hemolytic anemia. Leukemia & Lymphoma 2013; 54(7):1553-6.
  • Shvidel L, Tadmor T, Braester A, Bairey O, Rahimi-Levene, Herishanu Y, Klepfish A, Shtalrid M, Berrebi A, Polliack A, on behalf of the Israeli CLL Study Group (ICLLSG). Pathogenesis, Prevalence and Prognostic Significance of Cytopenias in Chronic Lymphocytic Leukemia (CLL): a Retrospective Comparative Study of 213 Patients From a National CLL Database of 1518 cases. Ann Hematol 2013 ;92(5):661-7.
  • T. Tadmor, L. Shvidel, A. Avivi, R. Ruchmeler, O. Bairey, Y. Herishanu, A. Braester, N. Levine, M. Yuklea, A. Poliack, on behalf of the Israeli CLL Study Group (ICLLSG) : Significance of bone marrow reticulin fibrosis in Chronic Lymphocytic Leukemia: a study of therapy "naïve" patients with prognostic implications. Cancer. 2013;119(10):1853-9.
  • L. Akria, V. Sonkin, E. Altman, C. Suriu, HI. Cohen, A. Braester: Amyloid tumor behaving as localized amyloidosis in a patient with long history of asymptomatic light chain myeloma. IMAJ 2013; 15(6):315-6.
  • D. Azoulay, D. Lavie, N. Horowitz, C. Suriu, M. Gatt, L. Akria, R. Perlman, A. Braester*, D. Ben Yehuda*. Bortezomib induced peripheral neuropathy is related to altered levels of brain derived neurotrophic factor in the peripheral blood of patients with multiple myeloma. Brit J Haematol 2014 ;164(3):454-6 (*These authors contributed equally to this study).
  • Shvidel L, Tadmor T, Braester A, Bairey O, Rahimi-Levene N, Herishanu Y, Klepfish A, Ruchlemer R, Berrebi A, Polliack A; the Israeli CLL Study Group. Serum immunoglobulin levels at diagnosis have no prognostic significance in stage A chronic lymphocytic leukemia: a study of 1113 cases from the Israeli CLL Study Group. Eur J Haematol; 2014, 93(1):29-33.
  • Lobo JL, Zorrilla V, Nieto JA, Gómez V, García-Bragado F, Bueso T, Braester A, Monreal M and the RIETE Investigators. Right atrial size and 30-day mortality in normotensive patients with pulmonary embolism. J Resp Pulm Med, 2014;4(6):.
  • Azoulay D, Sonkin V, Suriu C, Akria L, Braester A: Melanoma metastasis mimicking plasmocytoma in a patient with multiple myeloma. Ann Hematol Oncol 1(3), 2014.
  • Herishanu Y, Goldschmidt N, Bairey O, Ruchlemer R, Fineman R, Rahimi-Levene N, Shvidel L, Tadmor T, Ariel A, Braester A, Shapiro M, Joffe E, Polliack A. Efficacy and safety of frontline therapy with "FCR" regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group Experience. Haematologica, 2015. 100(5):662-9.
  • F. Marti-Martos, J. Trujillo-Santos, M. Barron, J. Vela, PJ. Marchena, A. Braester, D. Farge-Bancel, L. Hernandes-Blasco, P. Verhamme, M. Monreal. Gender differences in cancer patients with acute venous thromboembolism. Thromb Res 135 (supp 1), S12-S15, 2015.
  • Y. Ofran, K. Filanovsky, A. Gafter-Gvili, L. Vidal, A. Aviv, M. E. Gatt, I. Silbershatz, Y. Herishanu, A. Arad, T. Tadmor, A. Ronson, K. Herzog-Tzarfati, L. Akria, A. Braester, I. Hellmann, S. Yeganeh, A. Nagler, R. Leiba, M. Mittelman, D. Merkel Higher infection rate following seven compared to five day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk 2015; 15(6):e95-9.
  • Shvidel L, Bairey O, Tadmor T, Braester A, Ruchlemer R, Fineman R, Joffe E, Berrebi A, Polliack A; Israeli CLL Study Group. Absolute lymphocyte count with extreme hyperleukocytosis does not have a prognostic impact in chronic lymphocytic leukemia. Anticancer Res. 2015 May;35(5):2861-6.
  • D. Azoulay, A. Leibovici, R. Sharoni, E. Shaoul, B. Gross, A. Braester*, H. Goldberg*. Association between Met-BDNF allele and vulnerability to paclitaxel-induced peripheral neuropathy. Breast Cancer Res Treat. 2015 ; 153(3):703-4.
  • Ellis MH, Lavi N, Mishchenko E, Dally N, Lavie D, Courevitch A, Gutwein O, Bulvik S, Braester A, Chubar E, Tavor S, Duek A, Kirgner I, Koren-Michowitz M. Ruxolitinib treatment for myelofibrosis: Efficacy and tolerability in routine practice. Leuk Res. 2017;61:6-9
  • J. Portillo, De la Rocha, Font, A. Braester, O. Madridano, Díaz Peromingo, A. Apolloni, B. Pagán, J. Bascuñana. Venous thromboembolism in patients with glioblastoma multiforme. Findings of the RIETE registry. Thromb Res. 2015 Dec;136(6):1199-203.
  • Suriu C, Akria L, D. Azoulay, E. Shaoul, M. Barhoum, Braester A. Absolute lymphocyte count as a prognostic marker in newly diagnosed multiple myeloma patients treated in the era of novel agents. Int J Lab Hematol. 2016 Jun;38(3):e56-9.
  • Azoulay D,Sonkin V, Akria L, Shaoul E, Rozen S, Braester A. Flow cytometry detection of reactive plamocytosis and HRS-like cells as a challenging initial finding in angioimmunoblastic T cell lymphoma. J Hematopathol. 2016.9:101-103.
  • M. Mittelman, K. Filanovsky, Y. Ofran, H. Rosenbaum, P. Raanani, A. Braester, N. Goldshmidt, I. Kirgner, Y. Herishanu Ch. Perri, H. S. Oster, for The MDS Israel Group (MDS-IG). Azacitidine-Lenalidomide (ViLen) Combination Yields. High Response Rate in Higher-risk Myelodysplastic Syndromes (MDS) – ViLen-01 Protocol. Ann Hematol 2016;95(11):1811-8.
  • R. Rahav, S. Celia, O. Yakir, L. Akria, M. Barhoum *, A. Braester *. Physicians' lack of knowledge - a possible reason for red blood cell transfusion overuse? Isr J Health Policy Res. 2017;6(1):49.
  • Kuperman A, López-Reyes R, Bosco LJ, Lorenzo A, José B, Farge Bancel D, Alfonso M, Lumbierres M, Stemer G, Monreal Bosch M, Braester A; RIETE Investigators. Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism. J Thromb Thrombolysis. 2018 ;45(3):360-368.
  • M. Haran, V. Mirkin, A. Braester , N. Harpaz, O. Shvetz, M. Shtreiter-Greenberg, O. Mordich, O. Amram, I. Binsky, A. Marom, I Shachar, Y. Herishanu, S Ruchlemer,A.Berrebi, L. Valinsky , M. Shtalrid, L. Shvide. Aphase I-II clinical trial of the anti-CD74 monoclonal antibody milatuzumab in advanced/refractory chronic lymphocytic leukemia. A patient based approach. British Journal of Haematology, 2017
  • L. Akria, J. Chezar, S. Zisman-Rozen, EJ. Scheinman, Z.Zonis, Y. Hoffmann, T. Falik-Zaccai, L. Kalfon, M. Weiss, A. Braester, C. Suriu, M. Barhoum, A. Kuperman, E. Shaoul. A Puzzling "Switch" in Blood Following Blood Transfusion. Ann. Lab. Med. 2017;37:1-3.
  • Erel Joffe, Neta Goldschmidt, Osnat Bairey, Riva Fineman, Rosa Ruchlemer, Naomi Rahimi-Levene, Lev Shvidel, Uri Greenbaum, Ariel Aviv, Tamar Tadmor, Andrei Braester, Ariela Arad, Aaron Polliack and Yair Herishanu. Persistently Low Lymphocyte Counts after FCR Therapy for Chronic Lymphocytic Leukemia are Associated with Longer Overall Survival. Hematologic Oncology.2017.[Epub ahead of print].
  • E. Joffe, N. Goldschmidt, O. Bairey, R. Fineman, R. Ruchlemer,N. Rahimi-Levene, L. Shvidel, U. Greenbaum, A. Aviv, T.Tadmor,A. Braester, A. Arad, A. Polliack and Y. Herishanu. Outcomes of Second-Line Treatment After Frontline Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with Chronic Lymphocytic Leukemia Outside Clinical Trials. [Epub Ahead of Print], Eur J Haematol.
  • Tadmor T, Braester A, Najib D, Aviv A, Herishanu Y, Yuklea M, Shvidel L, Rahimi-Levene N, Ruchlemer R, Arad A, Fogl C, Henig C, Barak M, Magal L, Polliack A, Townsend K; Israeli CLL study group. A new risk model to predict time to first treatment in chronic lymphocytic leukemia based on heavy chain immunoparesis and summated free light chain. Eur J Haematol. 2019 [epub ahead of print].
  • P. Di Micco, G. Gussoni, F. Uressandi, A. Rivas, R. Lopez-Reyes, L. Mazzolai,Duce, A. Braester, P. Llamas, M. Monreal. Should we screen patients with unprovoked venous thromboembolism for hyperthyroidism? Report of several paradigmatic clinical cases from the RIETE registry. Archives of Hematology Case Report and Reviews. 2017.
  • Michelis R, Tadmor T, Barhoum M, Shehadeh M, Shvidel L, Aviv A, Stemer G, Dally N, Rahimi-Levene N, Yuklea M, Braester A. A C5a-Immunoglobulin complex in chronic lymphocytic leukemia patients is associated with decreased complement activity. PLoS One. 2019
  • D. Azoulay, Y. Herishanu, Shapiro M, Brenshaft Y, Suriu C, Akria L, A. Braester: Elevated serum BDNF levels are associated with favorable outcome in CLL patients: possible link to CXCR4 downregulation GLAL-2017-1072. Exp. Hematol. 2018.
  • A.Tufano, W. Ageno, P. Di Micco, F. Garcia-Bragado, A. Balloz, A. Braester, C. Ma Rubio, V. Isern, M. Monreal and RIETE Group. Outcome during anticoagulation in patients with symptomatic vs. incidental splanchnic vein thrombosis. Thrombosis Res.2018 .
  • Michal Inbar, Yair Herishanu, Neta Goldschmidt, Osnat Bairey, Mona Yuklea, Lev Shvidel, Riva Fineman, Ariel Aviv, Rosa Ruchlemer, Andrei Braester, Dali Najib, Ori Rouvio, Adir Shaulov, Uri Greenbaum, Aaron Polliack, Tamar Tadmor. Hairy Cell Leukemia: retrospective analysis of demographic data and outcome in 202 patients from 12 medical centers in Israel. Anticancer Res. 2018;38:6423-29.
  • Y. Herishanu, T. Tadmor, A. Braester, O. Bairey, A. Aviv, N. Rahimi-Levene, R. Fineman, I. Levi, M. Yuklea, R. Ruchlemer, L. Shvidel, A. Poliack. Low-Dose Fludarabine and Cyclophosphamide Combined with Standard Dose Rituximab (FCR-LITE) Is an Effective and Safe Regimen for Elderly Untreated Patients with Chronic Lymphocytic Leukemia: The Israeli CLL Study Group Experience. Hematol Oncol 2019. 37:185-192.
  • T. Tadmor, I. Levy, Y. Herishanu, N. Goldschmidt, O. Bairey, M. Yuklea, L. Shvidel, N. Rahimi-Levene, R. Ruchlemer, A. Braester, N. Dally, O. Rouvio, A. Shaulov, U. Greenbaum, M. Inbar, A. Polliack. Primary peg-filgrastim prophylaxis versus filgrastim given "on demand" during therapy with cladribine for hairy cell leukemia. Leuk Res 2019;82
  • A. Braester, M. Barhoum. Triple negative mutations in Essential Thrombocythemia with bcr-abl rearrangement: Is there a such distinct disease? Am J Med Sci. 2020 Mar;359(3):179-180.
  • M. Giorgi-Pierfranceschi, JJL. Núñez, M. Monreal, C. Cattabiani, C. Lodigiani, P. Di Mico, A. Braester, B. Bikdeli, S. Soler, F. Dentali. Morbid obesity and mortality in patients with venous thromboembolism. Findings from real life clinical practice. Chest, 2020. 157(6):1617-1625.
  • Y. Herishanu, A. Shaulov, R. Fineman, S. Bašić-Kinda, A. Aviv, E. Wasik-Szczepanek, O. Jaksic, M. Zdrenghea, U. Greenbaum, I. Mandac, M. Simkovic, M. Morawska, O. Benjamini, M. Spacek, A. Nemets, O. Bairey, A. Visentin, R. Ruchlemer, L. Laurenti, O. Stanca Ciocan, M. Doubek, L. Shvidel, N. Dali, F. Miras Calvo, A. De Meûter, M. Dimou, F. R. Mauro, M. Coscia, H. Bumbea, S. Róbert, T. Tadmor, O. Gutwein, M. Gentile, L. Scarfò, A. Tedeschi, P. Sportoletti, E. Gimeno Vázquez, J. Marquet Palomanes, S. Assouline, M. Papaioannou, A. Braester, L. Levato, M. Gregor, G. M. Rigolin, J. Loscertales, A. Medina Perez, M. R. Nijziel, V. M. Popov, R. Collado, I. Slavutsky, G. Itchaki, S. Ringelstein, N. Goldschmidt, C. Perry1, S. Levi, A. Polliack and P. Ghia. Front-line treatment with the combination obinutuzumab-chlorambucil for chronic lymphocytic leukemia in real-world clinical practice: results of a multinational, multicenter study by ERIC and the Israeli CLL study group (ICLLSG). Am J Hematol 2020. 95:604-611.
  • Michelis R, Tadmor T, Shvidel L, Aviv A, Stemer G, Shehadeh M, Barhoum M and Braester A. Cell-free IgG-aggregates in plasma of patients with chronic lymphocytic leukemia cause chronic activation of the classical complement pathway. PLOS ONE 2020.
  • Braester A, Bornstein J, Zverev A, Kukuyev Y, Stemer G, Barhoum M. Reassessment of venous thromboembolism risk and prophylaxis in post-delivery period of healthy women. Am J Med Sci. Am J Med Sci 2020. 360(5):604-606.
  • Catella-Chatron J, Bertoletti L, Mismetti P, Ollier E, Samperiz A, Soler S, JM Suriñach, Mahé I, Lorente MA, Braester A, Monreal M, for the investigators of the RIETE registry. Severe renal impairment and risk of bleeding during anticoagulation for venous thromboembolism J Thromb Haemost 2020;20(7):1728-1732.
  • A. Braester, L. Akria, O. Yakir, L. Shelev, M. Barhoum. Blood myths and ethnic cultural background are an impediment in patient blood management education. J Relig Health. 2020;59(6):2918-2927.
  • K. Filanovsky, M. Haran,, V. Mirkin, A. Braester, O. Shevetz, A. Stanevsky, E. Sigler, E. Votinov, Y. Zaltsman-Amir, H. Berrebi, A. Gross, L. Shvidel.Peripheral blood cell mitochondrial dysfunction in myelodysplastic syndrome can be improved by a combination of coenzyme Q10 and carnitine. Mediter J Hematol Infect Dis. 2020. 1;12(1):e2020072.
  • Braester A, Shturman A, Raviv B, Dorosinsky L, Rosenthal E, Atar S. What a family doctor must know about incidental finding of high mean platelet volume, metabolic syndrome and pre-diabetes. Isr Med Assoc J. 2021;23:754.
  • A. Braester, G. Stemer, S. Khouri, B. Raviv, M. Barhoum. High mean platelet volume does not aid in early diagnosis of venous thromboembolism in the Emergency Department. Isr Med Assoc J. 2021;23:1-4.
  • A. Braester, M. Barhoum. Implementation of patient blood management strategies in an Israeli hospital: caught between hope and despair. Isr Med Assoc J. 2021; 23: 198.
  • Naseraldeen N, Michelis R, Barhoum M, Chezar J, Tadmor T, Aviv A, Shvidel L, Litmanovich A, Shehade M, Stemer G, Shaoul E, Braester A. The role of Alpha Macroglobulin in IgG-aggregation and chronic activation of the complement system in patients with chronic lymphocytic leukemia. Frontiers in Immunology 2021; 11:603569.
  • Suriu C, Braester A, Barhoum M. Syndrome in a Patient with Essential Thrombocythemia – is it Always the Myeloproliferative Neoplasm to Blame? Arch Hematol Case Rep Rev 2021; 6(1): 005-006.
  • Suriu C, Braester A, Barhoum M. Acute panmyeliosis with myelofibrosis: the serpentine road to diagnosis. Ann Bone Marrow Res 2021; 6(1): 007-008.
  • Yamashita, Y, Bikdeli B, Monreal M, Morimoto T, Kato T, Ono K, Ancos C, López N, Juan J, Braester A, Mellado M, Kimura T. COMMAND VTE Registry Investigators; RIETE Investigators. Difference between Japanese and White Patients with Acute Pulmonary Embolism. Thromb Res. 2021;204:52-56.
  • Braester A, Shaul E, Mizrachi O, Akria L, Shelev L, Barhoum M. Patient involvement in the transfusion decision-making can change patient blood management practice for better or worse. Acta Haematologica 2021; 145:5–8.
  • Trujillo-Santos J, Pedrajas JM, Gomez-Cuervo C, Ballaz A, Braester A, Mahe I, Villalobos A, Porras JA, Monreal M. Enoxaparin versus dalteparin or tinzaparin in cancer patients with venous thromboembolism. The RIETECAT study. Res Pract Thromb Haemost. 2022. 3;6(4):e12736.
  • Benjamini O, Rokach L, Gilad I, Braester A, Shvidel L, Goldschmidt N, Shapira S, Dally N, Avigdor A, Rahav G, Lustig Y, Shapiro Ben David S, Fineman R, Paz A, Polliack A, Levy I, Tadmor T. Safety, efficacy and a response model to BNT162b mRNA Covid19 Vaccine in chronic lymphocytic leukemia patient Hematologica 2021 (Online ahead of print).
  • B. Bikdeli, D. Jimenez, P. Demelo-Rodriguez, F. Galeano-Valle, JA. Porras, R. Barba, C. Ay, R. Malý , A. Braester, E. Imbalzano, V. Rosa, R. Lecumberri, C. Siniscalchi, Á. Fidalgo, S. Ortiz, M. Monreal, for the RIETE Investigators. Venous Thrombosis within 30 Days After Vaccination Against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry. Viruses. 2022 18;14(2):178.
  • Braester A, Bilick A, Suriu C, Dally N, Barhoum M. Diagnostic value of neutrophil-lymphocyte ratio, lymphocyte-platelet ratio and mean platelet volume in third trimester pregnancy preeclampsia. Submitted
  • Braester A, Akria L, Suriu C, Barhoum M. Educating the educator about patient blood management. Transfus Apher Sci. 2022 (online ahead of print)
  • Herishanu Y, Rahav G, Levi S, Braester A, Itchaki G, Bairey O, Dali N, Shvidel L, Ziv-Baran T, Poliack A, Tadmor T, Benjamini O. Efficacy of a Third BNT162b2 mRNA COVID-19 Vaccine Dose in Patients with CLL who Failed Standard Two-dose Vaccination. Blood. 2022. 3;139(5):678-685.
  • Braester A, Barhoum M. Choosing wisely project and patient shared decision-making: between hammer and alvin. Isr Med Assoc J. 2021;23(11):699-703.
  • Levy I. Lavi A, Zimran E, Grisaro S, Aumann S, Itchaki G, Berger T, Raanani P, Harel R, Aviv A, Lavi N, Zuckerman T, Shvidel L, Jarchowsky O, Ellis M, Herzog T, Koren-Michowitz M, Sherf Y, Levi I, Sofer O, Shpilberg O, Deli N, Suriu C, Braester A, Ben Barouch S, Leiba M, Goldstein D, Sarid N, Yeganeh S, Halloun J, Mittelman M, Tadmor T. "COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome. Leukemia and Lymphoma 2021.62(14):3384-93.
  • Tadmor T, Benjamini O, Braester A, Rahav G, Rokach L. Antibody Persistence 100 days following the Second Dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia. Leukemia. 2021;35(9):2727-2730.
  • Braester A, Akria L, Suriu C, Barhoum M. Mental health in medicine students and physicians: do we need to worry? Submitted.
  • Braester A, Dally N, Suriu C, L. Akria, Barhoum M. After years of wandering, chronic myelomonocytic leukemia found finally its place. A mini-review. Accepted to Ha'Refuah. 2014.
  • Ruiz Sada P, Mazzolai L, Braester A, Ballaz A, Madridano O, Accassat S, Fernandez-Reyes JL, Lopez-Saed JB, Diaz-Pedroche MC, Monreal M and the RIETE Investigators. Venous thromboembolism in patients with autoimmune disorders: A comparison between bleeding complications during anticoagulation and recurrences after its discontinuation. Br J Haematol. 2022;197(4):489-496.
  • Regina Michelis, Lama Milhem, Evleen Galouk, Galia Stemer, Ariel Aviv, Tamar Tadmor, Mona Shehadeh, Lev Shvidel, Masad Barhoum, Andrei Braester. Increased Serum Level of Alpha-2 Macroglobulin and its production by B-Lymphocytes in Chronic Lymphocytic Leukemia. Frontiers in Immunology 2022.
  • Levi S, Bronstein Y, Goldschmidt N, Morabito F, Ziv-Baran T, Del Poeta G, Bairey O, Ilaria Del Principe M, Fineman R, Romana Mauro F, Gutwein O, Reda G, Ruchlemer R, Sportoletti P, Laurenti L, Shvidel L, Coscia M, Tadmor T, Varettoni M, Aviv A, Murru R, Braester A, Chiarenza A, Visentin A, Pietrasanta D, Loseto G, Zucchettii A, Bomben R, Olivieri J, Neri A, Rossi D, Gaidano G, Trentin L, Foà R, Cune A, Perry C, Gattei V, Gentile M, Herishanu Y. Efficacy of Front-line Ibrutinib versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. A Multicenter "Real-World" Study. Am J Hematol 2022.
  • Alper A*, Braester A* Perelman N, Dally N, Akria L, Suriu C, Barhoum M, Wacsman I. The role of blood inflammatory markers in the preoperative diagnosis of acute appendicitis. Int J Lab Hematol. 2024;46(1):58-62.
  • Braester A, Akria L, Zarfati M. Barhoum M. Patient blood management – it is impossible to ignore this policy. Ha'Refuah 2024;163(4):27-31.
  • D. Merkel, S. Soffer, K. Filanovsky , A. Braester, E. Fibach, Mutaz D, Y. Ofran, U. Greenbaum , A. Nagler , I. Amitai, M. Mittelman. The effect of the oral iron chelator deferiprone on iron overload and oxidative stress in patients with myelodysplastic syndromes A Study by the Israeli MDS working group. Acta Haematologica 2023.
  • Dally N, Baranes M, Akria L, Kashlikov M, Tarabia K, Sharabi-Nov, Suriu C, Braester A. Ethnic disparities in presentation but not outcome in multiple myeloma patients: a multicenter retrospective study in Northern Israel. Leukemia@Lymphoma.2023;64(13):2148-55.
  • Braester A, Suriu C, Akria L, Dally N, Barhoum M. Can an anemic patient be a partner to treatment decision-making? IMAJ 2023;25(11):766-768.
  • Braester A, Akria L, Suriu C, Dally N, Barhoum M, Tadmor T. The complement system and Chronic Lymphocytic Leukemia. Submitted
  • Braester A, Bilik A, Suriu C, Akria L, Dally N, Barhoum M. The role of blood inflammatory markers in identification of third trimester pregnant women, prone to develop pre-eclampsia. Accepted in IMAJ 2024
  • Braester A, Kasselman Yardena, Khouri Badra, Cohen Miriam, Barhoum Masad. Comptroller group for in hospital research survey – an Israeli Minister of Health unique and remarkable initiative. Submitted
  • Adrian Duek , Alexandra Tzinman , Kira Maziuk , Assaf Levy , Ronit Leiba, Galia Stemer, Adi Shacham Abulafia , Amos Cohen , Noa Lavi , Aaron Ronson , Andrei Braester, Shirley Shapira , Jonathan Canaani , Julia Volchek , Merav Leiba. Efficacy and Real-World Outcomes of Fedratinib Treatment in ruxolitinib-resistant or refractory patients with Primary Myelofibrosis: A national wide retrospective study. Accepted in Acta Haematologica 2024
  • Merckel D, Braester A, Antimicrobial Prophylaxis in Myelodysplastic Syndrome Patients treated with Azacitidine: Results of a Phase III Multicenter Randomized Placebo Controlled Study. Submitted
    No content available to display!!!